- Market Capitalization, $K 200,398
- Shares Outstanding, K 19,861
- Annual Sales, $ 146,650 K
- Annual Income, $ -24,490 K
- 60-Month Beta -2.15
- Price/Sales 1.39
- Price/Cash Flow N/A
- Price/Book 2.75
|Period||Period Low||Period High||Performance|
| || |
-0.39 (-3.78%)since 08/20/21
| || |
+0.06 (+0.61%)since 06/18/21
| || |
-1.41 (-12.44%)since 09/18/20
CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021
Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...
Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced a new observational study to understand...
STERIS (STE) is likely to have continued to gain from the robust demand of PPE and COVID-19-related products in Q4.
Centogene (CNTG) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical...
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.